At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 45 enrolled
Drug / intervention
Glecaprevir/Pibrentasvir (G/P)drug
Likely dose
Glecaprevir/Pibrentasvir (G/P) 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·interventional·Posted Aug 2, 2019·Updated Jul 11, 2024
In Brief
A Phase 2 clinical trial evaluating Glecaprevir/Pibrentasvir (G/P) for Hepatitis C Infection and HIV Infection. Completed, enrolled 45 participants across 12 sites in 2 countries.
Detailed Summary
The purpose of this study was to assess the efficacy of a fixed dose combination (FDC) of glecaprevir/pibrentasvir (G/P) given for 4 weeks for treatment of acute hepatitis C (HCV), with or without HIV-1 coinfection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Infection, HIV Infection
CountriesBrazil, United States
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartNov 2019
Primary CompletionMay 2023
Study CompletionAug 2023
TodayJul 2026
First PostedAug 2, 2019
Enrollment StartNov 20, 2019
Primary CompletionMay 18, 2023
Study CompletionAug 22, 2023
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.9 years ago
Interventions
Glecaprevir/Pibrentasvir (G/P)drug
Fixed-dose combination (FDC) tablets containing 100 mg of glecaprevir and 40 mg of pibrentasvir; administered as 3 tablets orally.